Table 1b.
Allogeneic Patient Demographics and Baseline Characteristics
| Home HCT (N=8) | Matched Controls (N= 16) | P-value1 | |
|---|---|---|---|
| Median Age (range) | 45.5 (29–63) | 50.5 (23–72) | 0.87 |
| Gender (female) | 5 (62.5%) | 7 (43.8%) | 0.39 |
| Race | 0.99 | ||
| White | 6 (75%) | 12 (75%) | · |
| Black | 2 (25%) | 3 (18.8%) | · |
| Other | 0 (0%) | 1 (6.3%) | · |
| Ethnicity (non-Hispanic) | 8 (100%) | 16 (100%) | · |
| Karnofsky Performance Status | 0.68 | ||
| 80 or below | 3 (37.5%) | 8 (50%) | · |
| 90–100 | 5 (62.5%) | 8 (50%) | · |
| Disease | 0.45 | ||
| Acute leukemia (AML+ALL)2 | 5 (62.5%) | 10 (62.5%) | · |
| Lymphoma (HL+NHL)3 | 1 (12.5%) | 0 (0%) | · |
| MDS/MPN4 | 2 (25%) | 6 (37.5%) | · |
| Disease Status | 0.56 | ||
| First Complete Remission | 4 (50%) | 7 (43.8%) | · |
| 2nd or greater CR5 | 0 (0%) | 3 (18.8%) | · |
| Partial Remission | 1 (12.5%) | 0 (0%) | · |
| Active | 1 (12.5%) | 3 (18.8%) | · |
| Stable | 2 (25%) | 3 (18.8%) | · |
| Myeloablative Conditioning | 7 (87.5%) | 15 (93.8%) | 0.57 |
| HLA Matching6/Donor Type | 0.99 | ||
| MUD7 | 1 (12.5%) | 2 (12.5%) | · |
| MRD8 | 6 (75%) | 11 (68.8%) | · |
| MMRD9 | 1 (12.5%) | 3 (18.8%) | · |
| MMUD10 | 0 (0%) | 0 (0%) | · |
| Stem Cell Source | 0.99 | ||
| Peripheral blood | 7 (87.5%) | 12 (75%) | · |
| Bone marrow | 1 (12.5%) | 3 (18.8%) | · |
| Cord blood | 0 (0%) | 1 (6.3%) | · |
| GVHD11 Prophylaxis | 0.89 | ||
| CNI/MMF12 | 0 (0%) | 1 (6.3%) | · |
| CNI/MTX13 | 5 (62.5%) | 10 (62.5%) | · |
| PTCy14 | 1 (12.5%) | 3 (18.8%) | · |
| Other | 2 (25%) | 2 (12.5%) | · |
| T Cell Depletion | 1 (12.5%) | 3 (18.8%) | 0.99 |
1
P-values obtained via t-test or Chi-square test.
2
Acute Leukemia: acute myeloid leukemia + acute lymphoblastic leukemia.
3
Lymphoma: Hodgkin Lymphoma + Non-Hodgkin Lymphoma.
4
MDS/MPN: Myelodysplastic Syndrome/ Myeloproliferative Neoplasm.
5
CR: Complete Remission.
6
HLA: Human Leukocyte Antigen.
7
MUD: Matched Unrelated Donor.
8
MRD: Matched Related Donor.
9
MMRD: Mismatched Related Donor.
10
MMUD: Mismatched Unrelated Donor.
11
GVHD: Graft-Versus-Host Disease.
12
CNI/MMF: Calcineurin Inhibitor/ Mycophenolate mofetil.
13
CNI/MTX: Calcineurin Inhibitor/ Methotrexate.
14
PTCy: Post-transplant Cyclophosphamide.